Amy M. VandenBerg
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (11)
Year:
2024
Year:
2024
First-line treatments for schizophrenia and schizoaffective disorder include antipsychotics and mood stabilizers, but their use may at times be limited due to severe adverse events. This case describes a 41-year-old male with a history of schizoaffective disorder and polysubstance use who was admitted to an inpatient psychiatry unit for acute manic and psychotic symptoms in the setting of absconding from his residential home and noncompliance with prescribed psychiatric medications. During his inpatient psychiatric hospitalization, he experienced DRESS (drug reaction with eosinophilia and systemic symptoms) with valproate, nephrogenic diabetes insipidus with lithium, potential neuroleptic malignant syndrome with risperidone, and orthostasis/tachycardia with clozapine. He ultimately achieved stabilization of manic and psychotic symptoms with loxapine without experiencing adverse events. This report highlights the potential utility of loxapine in individuals with schizoaffective disorder intolerant to standard mood-stabilizing and antipsychotic medications.
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Collaborators (3)
Erica A. K. Davis
University of Maryland School of Pharmacy
David Im
Clinical Assistant Professor
Michigan Medicine
Madison Irwin
University of Michigan
Make your next move.
Prepare your application
Review drafts before you send them.